{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:06:16Z","timestamp":1789023976373,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00415-026-14078-4","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T07:28:39Z","timestamp":1787297319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistent B-cell depletion after ublituximab for multiple sclerosis"],"prefix":"10.1007","volume":"273","author":[{"given":"Tereza","family":"Gabeli\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Te\u0161ija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0161an","family":"Sredanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Adamec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-1748","authenticated-orcid":false,"given":"Mario","family":"Habek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"14078_CR1","unstructured":"Galota F, Marcheselli S, De Biasi S, Gibellini L, Vitetta F, Fiore A, Smolik K, De Napoli G, Cardi M, Cossarizza A, Ferraro D. Impact of high-efficacy therapies for multiple"},{"key":"14078_CR2","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s40120-025-00784-0","volume":"14","author":"SL Hauser","year":"2025","unstructured":"Hauser SL, Cohen JA, de S\u00e8ze J, Meuth SG, Giacomini PS, Nakahara J, Oreja-Guevara C, Robertson D, Wray S, Bhatt A, Hu X, Xi J, Piccolo R, Jehl V, Sullivan R, Boer I, Wiendl H, Kappos L (2025) Five-year safety and efficacy outcomes with ofatumumab in patients with relapsing multiple sclerosis. Neurol Ther 14:1975\u20131992","journal-title":"Neurol Ther"},{"key":"14078_CR3","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","volume":"95","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, Traboulsee A, Wolinsky JS, Belachew S, Koendgen H, Levesque V, Manfrini M, Model F, Hubeaux S, Mehta L, Montalban X (2020) Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology 95:e1854\u2013e1867","journal-title":"Neurology"},{"key":"14078_CR4","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","volume":"87","author":"J Salzer","year":"2016","unstructured":"Salzer J, Svenningsson R, Alping P, Novakova L, Bj\u00f6rck A, Fink K, Islam-Jakobsson P, Malmestr\u00f6m C, Axelsson M, V\u00e5gberg M, Sundstr\u00f6m P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87:2074\u20132081","journal-title":"Neurology"},{"key":"14078_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2026.107373","volume":"113","author":"K Te\u0161ija","year":"2026","unstructured":"Te\u0161ija K, Sredanovi\u0107 M, Zanetti L, Gabeli\u0107 T, Adamec I, Barun B, KrbotSkori\u0107 M, Habek M (2026) Immunoglobulin dynamics and infection risk with ofatumumab versus ocrelizumab in multiple sclerosis. Mult Scler Relat Disord 113:107373","journal-title":"Mult Scler Relat Disord"},{"key":"14078_CR6","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.ekir.2025.02.002","volume":"10","author":"O Efe","year":"2025","unstructured":"Efe O, Sauvage G, Jeyabalan A, Al Jurdi A, Seethapathy HS, Cosgrove K, Cortazar FB, Laliberte KA, Zonozi R, Niles JL (2025) Persistent B cell depletion after rituximab for autoimmune and glomerular diseases: a case series. Kidney Int Rep 10:1441\u20131449","journal-title":"Kidney Int Rep"},{"key":"14078_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105009","volume":"79","author":"E Alvarez","year":"2023","unstructured":"Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM (2023) Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord 79:105009","journal-title":"Mult Scler Relat Disord"},{"key":"14078_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16331","author":"S Hallberg","year":"2024","unstructured":"Hallberg S, Evertsson B, Lillvall E, Boremalm M, de Flon P, Wang Y et al (2024) Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: a Swedish cohort study. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.16331","journal-title":"Eur J Neurol"},{"key":"14078_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00415-025-13133-w","volume":"272","author":"L Davies","year":"2025","unstructured":"Davies L, Shehadeh R, Watkins WJ, Jolles S, Robertson NP, Tallantyre EC (2025) Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. J Neurol 272:415","journal-title":"J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14078-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14078-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:16:42Z","timestamp":1789021002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-14078-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["14078"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14078-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"20 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TG: received consultation and\/or speaker fees from Biogen, Merck, Novartis, Roche. KT: nothing to disclose. MS: nothing to disclose. IA: received consultation and\/or speaker fees from Biogen, Merck, Novartis, Roche. MH: received consultation and\/or speaker fees from Biogen, Merck, Novartis, Roche, Astra Zeneca, Amgen.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to the policy of the Ethics Committee of the University of Zagreb School of Medicine, formal ethics committee approval is not required for the publication of a single anonymized case report. This case report was prepared in accordance with the ethical principles of the Declaration of Helsinki and applicable institutional guidelines.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for participation and for the publication of this case report, including any accompanying clinical data and images. A copy of the written informed consent is available for review by the journal upon request.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"536"}}